N-异丙基-5-[2-(4-吡啶基)乙炔基]-2-吡啶甲酰胺 | 1401031-52-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: N-异丙基-5-[2-(4-吡啶基)乙炔基]-2-吡啶甲酰胺
• 中文别名: N-异丙基-5-(吡啶-4-基乙炔基)吡啶酰胺
• 英文名称: N-Isopropyl-5-(pyridin-4-ylethynyl)picolinamide
• 英文别名: N-propan-2-yl-5-(2-pyridin-4-ylethynyl)pyridine-2-carboxamide
• CAS: 1401031-52-4
• 化学式: C₁₆H₁₅N₃O
• 分子量: 265.31
• InChiKey: STAFRSGTRKNXHF-UHFFFAOYSA-N

物化性质

• 溶解度：
  DMSO：可溶10mg/mL，澄清

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  54.9
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING DRUG ADDICTION AND PREVENTING A DRUG RELAPSE
  申请人：Arizona Board of Regents, for and on behalf of, Arizona State University

  公开号：US20150141462A1

  公开（公告）日：2015-05-21

  The present invention relates to pharmaceutical compositions comprising (a) a pharmaceutically effective amount of an mGluR5 positive allosteric modulator, derivative, prodrug or a pharmaceutically acceptable salt thereof; (b) a pharmaceutically effective amount of an agent selected from an NMDA partial agonist or a GlyT1 inhibitor, derivative, prodrug or a pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier. The present invention also relates to methods for treating drug addiction and preventing a drug relapse in a patient. The methods comprise (a) administering to the patient a pharmaceutically effective amount of an mGluR5 positive allosteric modulator, derivative, prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof; (b) administering to the patient a pharmaceutically effective amount of an agent selected from an NMDA partial agonist or a GlyT1 inhibitor, derivative, prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
• [EN] PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING DRUG ADDICTION AND PREVENTING A DRUG RELAPSE<br/>[FR] COMPOSITIONS PHARMACEUTIQUES ET MÉTHODES DE TRAITEMENT D'UNE PHARMACODÉPENDANCE ET DE PRÉVENTION À UNE RECHUTE MÉDICAMENTEUSE
  申请人：UNIV ARIZONA

  公开号：WO2013188465A2

  公开（公告）日：2013-12-19

  The present invention relates to pharmaceutical compositions comprising (a) a pharmaceutically effective amount of an mGluR5 positive allosteric modulator, derivative, prodrug or a pharmaceutically acceptable salt thereof; (b) a pharmaceutically effective amount of an agent selected from an NMDA partial agonist or a GlyT1 inhibitor, derivative, prodrug or a pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier. The present invention also relates to methods for treating drug addiction and preventing a drug relapse in a patient. The methods comprise (a) administering to the patient a pharmaceutically effective amount of an mGluR5 positive allosteric modulator, derivative, prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof; (b) administering to the patient a pharmaceutically effective amount of an agent selected from an NMDA partial agonist or a GlyT1 inhibitor, derivative, prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.